A recent medical study showed that vaccinating women during pregnancy against the respiratory syncytial virus (RSV), or giving infants a medication containing protective antibodies after birth, is associated with a reduced risk of infection and hospitalization due to complications in full-term newborns.
According to the study published yesterday Saturday in the scientific journal JAMA Network Open, the research was conducted by a team from the Vaccine Study Center of the Research Department at Kaiser Permanente in Northern California, United States, led by researcher Karen B. Jacobson. The study involved comparing data from 15,124 infants after matching groups according to specific criteria.
The results indicated no statistically significant difference between maternal vaccination during pregnancy and administering the drug Nirsevimab to the infant in preventing infection or hospitalization due to it, while both options were associated with reduced risks compared to receiving neither.
The respiratory syncytial virus is a common virus that can cause serious respiratory infections in infants, especially during the first few months of life. Vaccination during pregnancy helps transfer antibodies from the mother to the fetus, while Nirsevimab provides ready-made antibodies to the infant after birth, granting direct protection against the virus.
The study results highlight the importance of preventive measures against RSV in infants and their role in reducing infections and complications that may require hospitalization, with the need to determine the appropriate option according to approved medical guidelines and the condition of the mother and child.
Source: Syrian Arab News Agency (SANA)
Comments (0)